Sotrastaurin,425637-18-9

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Sotrastaurin

CAS No. : 425637-18-9

MCE 国际站：Sotrastaurin

产品活性：Sotrastaurin (AEB071) 是一种口服有效的 pan-PKC 抑制剂，作用于 PKCθ，PKCβ，PKCα，PKCη，PKCδ 和 PKCε，K_i 分别为 0.22 nM，0.64 nM，0.95 nM，1.8 nM，2.1 nM 和 3.2 nM。

研究领域：Epigenetics  |  TGF-beta/Smad

作用靶点：PKC

In Vitro: In cell-free kinase assays Sotrastaurin (AEB071) inhibits PKC, with K_i values in the subnanomolar to low nanomolar range. When Sotrastaurin is tested on a selected panel of kinases, the only enzyme on which Sotrastaurin displays an IC₅₀value below 1 μM is glycogen synthase kinase 3β. Sotrastaurin (AEB071) inhibits p-MARCKS, a PKC substrate, and pS6 in all the cell lines, independently of the mutational status. There is a slight inhibition of pERK at lower doses also in the GNA11 mutant cells, but not in the WT cells at any concentrations. This is consistent with previous reports indicating that Sotrastaurin inhibits ERK1/2 phosphorylation in GNAQ mutant cell lines.

In Vivo: The combination therapy results in a significantly enhanced reduction in tumor volume when compared to either Sotrastaurin (AEB071) or BYL719 alone (p=0.049 vs. BYL719 and p=0.022 vs. Sotrastaurin at day 26). There is even a greater effect when compared to vehicle control (p=0.016). Sotrastaurin (STN) treatment of liver donors and orthotopic liver transplantation (OLT) recipients (Gr.I) or of OLT recipients alone (Gr.II) prolongs animal survival, as 9 out of 10 rats in Gr. I, and 6 out of 6 rats in Gr.II survive >14 days. In contrast, only 4 out of 10 control OLT recipients remain alive at day 14 (p<0.01).

相关产品：Drug Repurposing Compound Library Plus  |  Clinical Compound Library Plus  |  Bioactive Compound Library Plus  |  Epigenetics Compound Library  |  Immunology/Inflammation Compound Library  |  Kinase Inhibitor Library  |  TGF-beta/Smad Compound Library  |  Anti-Cancer Compound Library  |  Clinical Compound Library  |  Drug Repurposing Compound Library  |  Reprogramming Compound Library  |  Oxygen Sensing Compound Library  |  Anti-COVID-19 Compound Library  |  Cytoskeleton Compound Library  |  Orally Active Compound Library  |  Neurodegenerative Disease-related Compound Library  |  Targeted Diversity Library  |  Rare Diseases Drug Library  |  Human Metabolite Library  |  Cancer Stem Cells Compound Library  |  Coagulation and Anti-coagulation Compound Library  |  Heterocyclic Compound Library  |  Membrane Protein-targeted Compound Library  |  Serine/Threonine Kinase Inhibitor Library  |  Phorbol 12-myristate 13-acetate  |  Forskolin  |  Staurosporine  |  Ionomycin  |  Go 6983  |  Midostaurin  |  Mitoxantrone  |  Fasudil Hydrochloride  |  Bisindolylmaleimide I  |  Rottlerin  |  Enzastaurin  |  Verbascoside  |  Afuresertib  |  Chelerythrine chloride  |  K-252a  |  Phorbol 12,13-dibutyrate  |  Hypericin  |  D-erythro-Sphingosine  |  Ingenol Mebutate  |  Ro 31-8220 mesylate  |  CGP60474  |  Darovasertib  |  Go6976  |  Ruboxistaurin  |  R59949  |  TPPB  |  NSC668394  |  DCP-LA

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds